Replies to post #207451 on Biotech Values

[dewophile]

re 3019

The pancreatic data can go either way of course, but that is a near term event and they have been increasing the number of centers recruiting FWIW. I still view it as a long shot but it could have legs

re IPF substudy i presume you mean the data w SOC. As long as there is safety there i wouldn't worry about numbers and duration of exposure wrt efficacy bc if there is efficacy as monotherapy vs placebo, based on a pretty unique MOA there would be very good reason to think combo would work out so i think positive efficacy as monotherapy vs placebo would be a strongly positive event for FGEN